{
    "clinical_study": {
        "@rank": "80760", 
        "arm_group": [
            {
                "arm_group_label": "1 BI 1181181 low dose", 
                "arm_group_type": "Experimental", 
                "description": "tablet"
            }, 
            {
                "arm_group_label": "BI 1181181 high dose", 
                "arm_group_type": "Experimental", 
                "description": "tablet"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the reduction of \u00df-amyloid levels in cerebrospinal fluid and plasma and to\n      evaluate pharmacokinetics, safety and tolerability following single oral doses of BI\n      1181181."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males according to the investigator\u00b4s assessment, as based on the following\n             criteria: a complete medical history including a physical examination, vital signs\n             (BP, PR), 12-lead ECG, and clinical laboratory tests\n\n          2. Age 18 to 50 years (incl.)\n\n          3. BMI 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including BP, PR or ECG) deviating from\n             normal and judged clinically relevant by the investigator\n\n          2. Repeated measurement of systolic blood pressure < 90 mmHg and >= 140 mmHg at\n             screening in supine position\n\n          3. Repeated measurement of diastolic blood pressure < 55 and >= 90 mmHg at screening in\n             supine position\n\n          4. Repeated measurement of pulse rate < 40 bpm and > 90 bpm at screening\n\n          5. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          6. Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          7. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          8. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial\n             drug\n\n          9. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders\n\n         10. History of relevant orthostatic hypotension, fainting spells, or blackouts\n\n         11. Chronic or relevant acute infections\n\n         12. Positive testing on infectious diseases\n\n         13. History of relevant allergy/hypersensitivity (including allergy to the trial\n             medication or its excipients)\n\n         14. Intake of drugs with a long half-life (>24 hours) within 30 days or less than 10\n             halflives of the respective drug prior to administration of trial medication\n\n         15. Within 10 days prior to administration of trial medication, use of drugs that might\n             reasonably influence the results of the trial\n\n         16. Participation in another trial with investigational drug administration within 60\n             days prior to administration of trial medication\n\n         17. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)\n\n         18. Inability to refrain from smoking on trial days\n\n         19. Alcohol abuse (consumption of more than 40 g per day)\n\n         20. Drug abuse\n\n         21. Positive testing in the alcohol breath test or the drug screening test\n\n         22. Blood donation (more than 100 mL within 30 days prior to administration of trial\n             medication or during the trial)\n\n         23. Intention to perform excessive physical activities within one week prior to\n             administration of trial medication or during the trial\n\n         24. Inability to comply with dietary regimen of trial site\n\n         25. At screening, a marked baseline prolongation of QT/QTc interval (such as repeated\n             demonstration of a QTcF interval >450 ms) or any other relevant ECG finding\n\n         26. A history of additional risk factors for Torsades de Pointes (such as heart failure,\n             hypokalemia, or family history of Long QT Syndrome)\n\n         27. Abnormal parameters for thyroid hormones (T3, T4, TSH), coagulation parameters\n             (partial thromboplastin time (aPTT), prothrombin time (PT) and fibrinogen (retests\n             prior inclusion are allowed))\n\n         28. Subject is assessed by the investigator as unsuitable for inclusion, for instance,\n             because considered not able to understand and comply with study requirements, or has\n             a condition that would not allow safe participation in the study\n\n         29. Male subjects who do not agree to minimize the risk of female partners becoming\n             pregnant from the first dosing day until two month after the trial completion.\n             Acceptable methods of contraception comprise barrier contraception and a medically\n             accepted contraceptive method for the female partner (intra-uterine device with\n             spermicide, hormonal contraceptive for at least two month prior trial participation)\n\n         30. History of retinopathy\n\n         31. Any history or present disease of the central nervous system, the spinal cord or the\n             spinal column, which could provoke complications with procedure of the lumbar\n             catheterization/intrathecal punction\n\n         32. Signs of intracranial overpressure as determined by funduscopy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106247", 
            "org_study_id": "1344.20", 
            "secondary_id": "2013-004563-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 1181181 high dose", 
                "description": "two tablet", 
                "intervention_name": "BI 1181181 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1 BI 1181181 low dose", 
                "description": "one tablet", 
                "intervention_name": "BI 1181181 low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium"
                }, 
                "name": "1344.20.32001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal and Health Products"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "%-change from baseline of A\u00df1-40 in cerebrospinal fluid at the end of the dosing interval (i.e., 24 hrs post dose) (PoM)", 
            "safety_issue": "No", 
            "time_frame": "up to 24 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106247"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma and cerebrospinal fluid over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma and cerebrospinal fluid)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma and cerebrospinal fluid (if possible) over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}